胱抑素C在131I治疗甲亢中的应用价值

目的 探讨胱抑素C在131I治疗甲亢中的临床应用价值.方法 选择2011年2月至2012年10月在我院131I治疗的43例甲亢患者和40例健康者（对照组）进行甲状腺激素、血清胱抑素C（CysC）水平的比较;并观察甲亢患者131I治疗后3个月、6个月与治疗前的甲状腺激素、血清胱抑素C（CysC）与血清肌酐（Cr）水平变化.结果 甲亢患者血清CysC水平增高,随着甲亢患者131I治疗后甲状腺激素水平的恢复,血清CysC水平降低（P＜0.05）.结论 血清胱抑素C（CysC）可以作为甲亢的辅助检测项目和131I治疗后疗效判定的辅助诊治指标.     

131I联合泼尼松龙片治疗Graves病的疗效分析

目的 探讨Graves病用131I治疗与131I联合泼尼松龙片治疗的疗效差异,比较131 I联合泼尼松龙片在Graves病患者治疗中的临床价值.方法 选择行131 I治疗的两组Graves病患者.A组给予131 I二周后,给予泼尼松龙片5mg,1次/日,口服,共6周.B组给予131I治疗,不给予泼尼松龙片治疗.两组患者在治疗中依病情给予甲巯咪唑片及比索洛尔片对症处理,比较两组治愈率、治愈所需的时间,治疗过程中甲巯咪唑片及比索洛尔片使用的剂量.结果 联合运用泼尼松龙的A组治愈率与B组比较差异不显著,但甲状腺功能恢复正常所需的时间、甲巯咪唑片及比索洛尔片对症处理所需的剂量明显低于B组,差异有统计学意义（P＜0.05）.结论 泼尼松龙联合131I治疗Graves病疗效显著,能较快的改善自觉症状,减少早期并发症.     

β-HCG检测在拟行131I治疗育龄期女性甲亢患者中的临床意义

目的 探讨β-HCG检测在拟行131I治疗育龄期女性甲亢患者中的临床价值.方法 对拟行131 I治疗的420例育龄期女性甲亢患者的临床资料及血清β-HCG、FT3、FT4、TSH结果进行回顾性分析.结果 18 ～ 35岁年龄段各组的女性甲亢患者β-HCG阳性率比较,差异无统计学意义（P ＞0.05）;36～40岁年龄段组与18 ～ 35岁年龄段组女性甲亢患者β-HCG阳性率比较,差异有统计学意义（P＜0.01）;月经减少、紊乱或闭经组β-HCG水平明显高于月经正常组（P＜0.01）;月经正常组与月经减少、紊乱或闭经组的FT3、TSH4、TSH水平比较,差异无统计学意义（P＞0.05）.结论 月经减少、紊乱或闭经的育龄期甲亢患者更可能合并妊娠,育龄期女性甲亢患者在拟行131I治疗前应常规检测血清β-HCG,防止早孕的漏诊,避免误治.     

131I治疗结节性甲状腺肿并甲亢260例临床分析

目的 对131I治疗结节性甲状腺肿并甲亢的效果进行临床分析.方法 对确诊为结节性甲状腺肿并甲亢的260例患者采用131I治疗,结合结节情况、甲状腺吸碘率、甲状腺重量及甲状腺B超检查等确定131I剂量,并随访3～60个月.2～6个月复查甲功,根据甲功情况给予左甲状腺素钠片25 ～ 150μg/日,抑制TSH增高及治疗甲减.结果 260例患者131I甲亢治愈率为65.39％ （170/260）,甲亢好转率为20.00％ （52/260）,甲减发生率14.61％ （38/260）,总体有效率100％（含甲减）;131I治疗后结节消除占78.85％ （205/260）,结节缩小占15.39％ （40/260）,结节治疗无效占5.77％ （15/260）.结节直径越小的疗效越好（P＜0.05）.结论 131I治疗结节性甲状腺肿并甲亢疗效较好,适合有手术禁忌证或拒绝手术的患者.     

Does Infection Initiate Graves Disease?: A Population Based 10 Year Study

In order to detect whether micro-organisms could initiate the autoimmune process in Graves' disease we have studied the temporal and spatial distribution of 857 cases of hyperthyroidism occurring in a community over ten years. Cases were identified through biochemistry laboratory records and following the exclusion of patients with toxic nodular goitre or with insufficient clinical data there were 599 with Graves' disease - an average annual incidence of 15.9 per 100,000. There was a tendency for cases to present in the summer months. The reported onset of symptoms, however, peaked in December and June. There was no evidence of clustering of cases in space and time using two different statistical methods. Incidence rates doubled between 1976 and 1980 and then declined - a trend that could neither be explained by changes in laboratory or clinical diagnosis nor did it correlate with any pattern of microbial disease in the area.

We conclude that it is unlikely that infections that behave in an epidemic manner have a causative role in triggering Graves' disease.     

甲亢诊断指数与甲亢患者甲状腺功能及自身抗体水平相关探讨

目的探讨甲亢诊断指数与甲亢患者甲状腺功能及自身抗体水平相关性。方法采用甲亢诊断指数表收集临床甲亢患者500例,为每位患者进行实验室的数据检查,采用统计学方法分析甲亢诊断指数与甲亢患者的甲状腺功能和自身抗体水平的相关性。结果甲亢诊断指数中的各个因子均能进入方程,并不同程度地反应了甲状腺功能和自身抗体水平。结论采用甲亢诊断指数简易表能够很好地预测甲亢患者的甲状腺功能及其自身的抗体水平,可作为临床筛选患者的一种方法。     

甲状腺的手术治疗与并发症预防

目的：探讨甲状腺功能亢进症围术期的治疗,降低严重并发症的发生率。方法：回顾性分析本院2008年1月～2010年12月收治入院的80例经内科治疗无效甲状腺功能亢进症患者,给予完善检查,术前准备,行甲状腺次全切除术后进行资料分析。结果：80例患者术后出血1例,喉上神经分支损伤2例,喉返神经损伤1例,引起四肢抽搐4例。75例治愈,4例复发,1例死亡,无甲状腺危象及声音嘶哑。结论：术前完善准备,术中精心操作,配合用药,可减少和避免并发症的发生。     

Enuresis in hyperthyroidism: a temporary lack of central control mechanism leads to nocturnal enuresis

We report on a 9-year-old boy who suffered from hyperthyroidism and a new appearance of enuresis. Bedwetting ceased and prepulse inhibition (PPI) – measured as a parameter of central control – increased during the course of therapy.
Conclusion:  The increase in PPI is an indication that enuresis in hyperthyroidism could be as a result of a temporary loss of central control on brainstem reflexes. The case conveys new insights into the correlation between thyroid hormones and micturition patterns and the aetiology of enuresis.     

Thyrotoxic Periodic Paralysis: A Case Report and Literature Review

We describe a 37-year-old man with a 4-month history of episodic muscular weakness, involving mainly lower-limbs. Hypokalemia was documented in one episode and managed with intravenous potassium chloride. Hyperthyroidism was diagnosed 4 months after onset of attacks because of mild symptoms. The patient was subsequently diagnosed as having thyrotoxic periodic paralysis associated with Graves’ disease. Treatment with propranolol and methimazol was initiated and one year later he remains euthyroid and symptom free. Thyrotoxic periodic paralysis is a rare disorder, especially among Caucasians, but it should always be considered in patients with acute paralysis and hypokalemia, and thyroid function should be evaluated.     

复方皂矾丸治疗甲状腺功能亢进症并发白细胞减少62例

目的 观察复方皂矾丸治疗甲状腺功能亢进症（甲亢）并发白细胞减少症的临床疗效. 方法 将116例甲亢并白细胞减少症患者随机分为两组,治疗组62例,对照组54例. 治疗组给予复方皂矾丸9粒,po,tid;对照组给予口服利血生20 mg ,tid,维生素B₄ 20 mg ,tid. 两组均2周为1个疗程,共治疗2个疗程. 观察两组治疗后相同时间白细胞恢复情况. 结果 治疗组服用复方皂矾丸的总有效率为83.87%,而对照组总有效率为61.11%,差异有显著性（P＜0.05）. 治疗组白细胞总数升高比对照组显著（P＜0.01）. 治疗组中偶见有轻微胃部不适反应. 结论 复方皂矾丸可作为甲亢并白细胞减少症治疗效果较好的药物,有利于甲亢患者抗甲状腺药物的顺利进行,值得临床推荐使用.